Neurostimulation Devices Market Report 2026

Neurostimulation Devices Market Overview

• Neurostimulation Devices market size has reached to $6.86 billion in 2025 • Expected to grow to $12.03 billion in 2030 at a compound annual growth rate (CAGR) of 12% • Growth Driver: Expanding Healthcare Industry Driving Growth In The Neurostimulation Devices Market • Market Trend: Adoption of Closed Loop Spinal Cord Stimulation Systems for Adaptive Chronic Pain Therapy • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Neurostimulation Devices Market?

Neurostimulation devices are medical instruments used to deliver electrical impulses to specific parts of the nervous system to modulate nerve activity. These devices are commonly implanted in or placed on the body to treat various neurological conditions. Neurostimulation works by altering or blocking pain signals or by stimulating certain neural pathways to restore function. These devices are designed to improve patients' quality of life by providing targeted and adjustable therapy. The main products of the neurostimulation devices are implantable devices and external devices. The implantable devices involved are cochlear implants, deep brain stimulation, spinal cord stimulation, vagus nerve stimulation, sacral nerve stimulation, and gastric electric stimulation and the external devices are transcranial magnetic stimulation (TMS) and transcutaneous electrical nerve stimulation (TENS). The various applications of implantable devices are pain management, epilepsy, essential tremor, urinary and fecal incontinence, depression, dystonia, gastroparesis, and Parkinson's disease.

What Is The Neurostimulation Devices Market Growth Forecast?

The neurostimulation devices market size is expected to see rapid growth in the next few years. It will grow to $12.03 billion in 2030 at a compound annual growth rate (CAGR) of 12.0%. The growth in the forecast period can be attributed to increasing demand for personalized neuromodulation therapies, rising adoption of minimally invasive neurostimulation devices, growing investments in brain-computer interface research, expansion of home-based neuromodulation treatments, increasing regulatory approvals for novel stimulation indications. Major trends in the forecast period include increasing adoption of closed-loop neurostimulation systems, rising use of personalized neuromodulation therapies, growing integration of wireless and miniaturized implants, expansion of external non-invasive stimulation devices, enhanced focus on long-term therapy adjustability.

Global Neurostimulation Devices Market Segmentation

1) By Product: Implantable Devices, External Devices 2) By Application: Pain Management, Epilepsy, Essential Tremor, Urinary and Fecal Incontinence, Depression, Dystonia, Gastroparesis, Parkinson's Disease 3) By End User: Hospitals, Rehabilitation Centers, Medical Clinic Subsegments: 1) By Implantable Devices: Spinal Cord Stimulators (SCS), Deep Brain Stimulators (DBS), Vagus Nerve Stimulators (VNS), Sacral Nerve Stimulators (SNS) 2) By External Devices: Transcranial Magnetic Stimulation (TMS) Devices, Transcranial Direct Current Stimulation (tDCS) Devices, Cranial Electrotherapy Stimulation (CES) Devices

What Is The Driver Of The Neurostimulation Devices Market?

Growing demand in the healthcare industry is expected to propel the growth of the neurostimulation devices market going forward. The healthcare industry is a vast and multifaceted sector of the economy that encompasses various organizations, professionals, and institutions dedicated to providing medical services, healthcare products, and the overall maintenance and improvement of people's health. Neurostimulation devices have several essential uses in the healthcare industry, particularly in treating and managing various neurological conditions and chronic pain. For instance, in May 2023, according to a report published by the Office for National Statistics, a UK-based government department, between 2022 and 2023, healthcare spending in the UK increased by 5.6% compared with growth of 0.9% in 2022. The UK healthcare expenditure in UK healthcare expenditure was around $ 322.152 billion (£292 billion) in 2023. Therefore, the growing healthcare industry is driving the growth of the neurostimulation devices industry.

Key Players In The Global Neurostimulation Devices Market

Major companies operating in the neurostimulation devices market are Medtronic plc, Cyberonics Inc., Boston Scientific Corporation, Abbott Laboratories, Nevro Corporation, Neuronetics Inc., NeuroPace Inc., NeuroSigma Inc., NDI Medical LLC, Synapse Biomedical Inc., MED-EL, LivaNova PLC, Aleva Neurotherapeutics, BrainsWay, Cortec Corporation, Endonovo Therapeutics Inc., Inspire Medical Systems Inc., The Magstim Company Limited, Mainstay Medical Limited, MicroTransponder Inc., MindMaze, NeuroMetrix, Nexeon MedSystems, Nuvectra, Saluda Medical, SPR Therapeutics Inc., Uro Medical Corporation

Global Neurostimulation Devices Market Trends and Insights

Major companies operating in the neurostimulation devices market are focusing on closed loop spinal cord stimulation (SCS) systemsto deliver adaptive therapy that better aligns with patients’ daily movements. Closed loop SCS refers to systems that sense physiological signals along the spinal cord and automatically adjust stimulation in real time, instead of delivering fixed-output electrical pulses. For instance, in April 2024, Medtronic plc, a US based healthcare technology company, received FDA approval for its Inceptiv closed-loop rechargeable spinal cord stimulator. The device features real time sensing of biological signals, automatically adjusts stimulus intensity, offers multiple waveforms (including its proprietary DTM therapy), and allows full body 3T MRI access.

What Are Latest Mergers And Acquisitions In The Neurostimulation Devices Market?

In November 2024, Medtronic plc, an Ireland based medical device company, acquired Fortimedix Surgical for an undisclosed amount. With this acquisition, Medtronic aims to strengthen its surgical and endoscopy portfolio, particularly to complement its upcoming Hugo soft-tissue robotic system. Fortimedix is a Netherlands-based company that offers neurostimulation devices.

Regional Outlook

North America was the largest region in the global neurostimulation devices market in 2025. Asia-Pacific was the second-largest region in the neurostimulation devices market. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are China, India, Japan, Australia, Indonesia, South Korea, Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, Taiwan, New Zealand, UK, Germany, France, Italy, Spain, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Russia, Czech Republic, Poland, Romania, Ukraine, USA, Canada, Mexico, Brazil, Chile, Argentina, Colombia, Peru, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.

What Defines the Neurostimulation Devices Market?

The neurostimulation devices market consists of sales of spinal cord stimulators, deep brain stimulators, sacral nerve stimulators, vagus nerve stimulators, and others. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.